Published in Clin Exp Med on November 11, 2010
Nanobody: the "magic bullet" for molecular imaging? Theranostics (2014) 1.04
Celastrus and its bioactive celastrol protect against bone damage in autoimmune arthritis by modulating osteoimmune cross-talk. J Biol Chem (2012) 1.01
Adipokines in psoriatic arthritis patients: the correlations with osteoclast precursors and bone erosions. PLoS One (2012) 0.95
Chemokine expression is upregulated in chondrocytes in diabetic fracture healing. Bone (2012) 0.91
Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective. Int J Med Sci (2012) 0.88
Hypoxia-inducible factor-2α is an essential catabolic regulator of inflammatory rheumatoid arthritis. PLoS Biol (2014) 0.88
Bone effects of biologic drugs in rheumatoid arthritis. Clin Dev Immunol (2013) 0.86
Immunomodulatory effects of vitamin D in peripheral blood monocyte-derived macrophages from patients with rheumatoid arthritis. Clin Exp Med (2013) 0.81
Sinomenine suppresses osteoclast formation and Mycobacterium tuberculosis H37Ra-induced bone loss by modulating RANKL signaling pathways. PLoS One (2013) 0.79
1,25-dihydroxyvitamin D3 inhibits the RANKL pathway and impacts on the production of pathway-associated cytokines in early rheumatoid arthritis. Biomed Res Int (2013) 0.77
The standardized BHH10 extract, a combination of Astragalus membranaceus, Cinnamomum cassia, and Phellodendron amurense, reverses bone mass and metabolism in a rat model of postmenopausal osteoporosis. Phytother Res (2014) 0.76
Interleukin-21 promotes osteoclastogenesis in RAW264.7 cells through the PI3K/AKT signaling pathway independently of RANKL. Int J Mol Med (2016) 0.75
Osteoclast differentiation and activation. Nature (2003) 18.59
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell (1997) 15.96
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell (2002) 9.10
The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature (1990) 8.94
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature (1997) 8.59
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature (1999) 8.23
Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69
IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest (1999) 7.66
International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev (2000) 7.17
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol (2007) 5.86
TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest (2000) 5.78
Regulation of cancer cell migration and bone metastasis by RANKL. Nature (2006) 5.27
Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood (2000) 5.06
Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J Exp Med (1993) 4.94
Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature (2004) 4.92
Modulation of osteoclast differentiation. Endocr Rev (1992) 4.27
IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest (2005) 3.56
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol (2001) 3.53
Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum (2000) 3.51
The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci U S A (2004) 3.15
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res (1996) 2.86
Osteoclasts are essential for TNF-alpha-mediated joint destruction. J Clin Invest (2002) 2.85
Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol (2006) 2.73
Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum (2000) 2.61
B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol (2006) 2.56
Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J (2001) 2.37
Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J Clin Invest (2004) 2.31
Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun (1999) 2.28
Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol (2007) 2.27
Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med (2005) 2.21
c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. J Clin Invest (2003) 2.19
Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem (2000) 2.18
B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood (2007) 2.16
IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res (2001) 2.12
Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol Rev (2005) 2.08
A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med (2002) 2.04
JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci (2002) 1.99
Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol (1999) 1.96
Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages: a possible role in rheumatoid arthritis. Arthritis Rheum (2000) 1.96
Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum (2001) 1.85
Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum (1984) 1.85
Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat Med (2009) 1.81
Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. Arthritis Rheum (2005) 1.75
Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines. Blood (2000) 1.74
A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun (1999) 1.72
MafB negatively regulates RANKL-mediated osteoclast differentiation. Blood (2006) 1.60
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood (2005) 1.59
The role of T lymphocytes in bone metabolism. Immunol Rev (2005) 1.53
Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood (2004) 1.50
Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem (2000) 1.49
Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood (2002) 1.47
Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res (2001) 1.47
Osteoclasts; culprits in inflammatory osteolysis. Arthritis Res Ther (2005) 1.43
IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther (2007) 1.40
The molecular scaffold Gab2 is a crucial component of RANK signaling and osteoclastogenesis. Nat Med (2005) 1.39
Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol (2001) 1.38
Id helix-loop-helix proteins negatively regulate TRANCE-mediated osteoclast differentiation. Blood (2005) 1.38
Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev (2005) 1.36
Osteoclasts, rheumatoid arthritis, and osteoimmunology. Curr Opin Rheumatol (2006) 1.35
Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) (2005) 1.33
A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun (1997) 1.33
Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc Natl Acad Sci U S A (2007) 1.32
Transforming growth factor-beta stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem (1998) 1.31
Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood (2002) 1.31
Bacterial-responsive B lymphocytes induce periodontal bone resorption. J Immunol (2006) 1.30
CXCR3 expression and activation of eosinophils: role of IFN-gamma-inducible protein-10 and monokine induced by IFN-gamma. J Immunol (2000) 1.30
Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression. Proc Natl Acad Sci U S A (2005) 1.25
Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors. J Immunol (2009) 1.25
FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner. J Clin Invest (2005) 1.25
Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol (2001) 1.22
IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression. J Immunol (2009) 1.19
Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum (2003) 1.17
Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J Pathol (2007) 1.16
Microphthalmia transcription factor and PU.1 synergistically induce the leukocyte receptor osteoclast-associated receptor gene expression. J Biol Chem (2003) 1.14
Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res (2003) 1.14
Dendritic cells and the pathogenesis of rheumatoid arthritis. J Leukoc Biol (1999) 1.13
A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther (2003) 1.11
Receptor activator of NF-kappaB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett (1999) 1.11
Generation of bone-resorbing osteoclasts from B220+ cells: its role in accelerated osteoclastogenesis due to estrogen deficiency. J Bone Miner Res (2001) 1.10
Reciprocal cross-talk between RANKL and interferon-gamma-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum (2008) 1.10
Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum (2010) 1.05
Peripheral blood T lymphocytes from patients with early rheumatoid arthritis express RANKL and interleukin-15 on the cell surface and promote osteoclastogenesis in autologous monocytes. Arthritis Rheum (2006) 1.03
Murine osteoclast formation and function: differential regulation by humoral agents. Endocrinology (2005) 1.03
Angiogenesis and chemokines in rheumatoid arthritis and other systemic inflammatory rheumatic diseases. J Cell Mol Med (2002) 1.01
Autoimmunity and bone. Ann N Y Acad Sci (2006) 0.98
B lymphocytes inhibit human osteoclastogenesis by secretion of TGFbeta. J Cell Biochem (2000) 0.98
The dynamic interplay between osteoclasts and the immune system. Arch Biochem Biophys (2008) 0.97
Association of the OSCAR promoter polymorphism with BMD in postmenopausal women. J Bone Miner Res (2005) 0.95
Monokine induced by interferon-gamma is induced by receptor activator of nuclear factor kappa B ligand and is involved in osteoclast adhesion and migration. Blood (2004) 0.90
Induction of osteoclast-associated receptor, a key osteoclast costimulation molecule, in rheumatoid arthritis. Arthritis Rheum (2008) 0.90
Mechanisms of interferon-beta effects on bone homeostasis. Biochem Pharmacol (2009) 0.89
Interleukin-15 and interferon-gamma participate in the cross-talk between natural killer and monocytic cells required for tumour necrosis factor production. Arthritis Res Ther (2006) 0.89
Denosumab. MAbs (2009) 0.89
Ligation of the FcR gamma chain-associated human osteoclast-associated receptor enhances the proinflammatory responses of human monocytes and neutrophils. J Immunol (2006) 0.86
B cells activated in the presence of Th1 cytokines inhibit osteoclastogenesis. Exp Mol Med (2003) 0.83
Cells expressing dendritic cell markers are present in the rheumatoid nodule. J Rheumatol (2000) 0.81
Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients. Int J Cancer (2004) 1.76
Extra-skeletal effects of bisphosphonates. Joint Bone Spine (2006) 1.59
Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood (2005) 1.59
Osteoblast physiology in normal and pathological conditions. Cell Tissue Res (2010) 1.49
Oxytocin is an anabolic bone hormone. Proc Natl Acad Sci U S A (2009) 1.44
Activation of the receptor activator of the nuclear factor-κB ligand pathway during coronary bypass surgery: comparison between on- and off-pump coronary artery bypass surgery procedures. Eur J Cardiothorac Surg (2013) 1.41
Osteocalcin: skeletal and extra-skeletal effects. J Cell Physiol (2013) 1.31
Vitamin D and the immune system. J Rheumatol (2010) 1.22
Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia. Proc Natl Acad Sci U S A (2013) 1.17
Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol (2002) 1.17
Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J (2004) 1.08
Bone marrow oxytocin mediates the anabolic action of estrogen on the skeleton. J Biol Chem (2012) 1.05
Dehydroepiandrosterone stimulates glucose uptake in human and murine adipocytes by inducing GLUT1 and GLUT4 translocation to the plasma membrane. Diabetes (2004) 1.03
Periodontal disease: linking the primary inflammation to bone loss. Clin Dev Immunol (2013) 1.03
Microgravity during spaceflight directly affects in vitro osteoclastogenesis and bone resorption. FASEB J (2009) 1.02
Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. J Cell Sci (2002) 1.02
T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood (2004) 1.02
Regulated production of the pituitary hormone oxytocin from murine and human osteoblasts. Biochem Biophys Res Commun (2011) 0.99
Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem (2005) 0.98
Cellular mechanisms of multiple myeloma bone disease. Clin Dev Immunol (2013) 0.96
Human osteoclasts express oxytocin receptor. Biochem Biophys Res Commun (2002) 0.95
Multiprofessional and intrahospital experience for diagnosis and treatment of pulmonary arterial hypertension. Monaldi Arch Chest Dis (2012) 0.95
IL-7 up-regulates TNF-alpha-dependent osteoclastogenesis in patients affected by solid tumor. PLoS One (2006) 0.95
The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis (2007) 0.94
Sclerostin is overexpressed by plasma cells from multiple myeloma patients. Ann N Y Acad Sci (2011) 0.94
Gorham-Stout syndrome: a monocyte-mediated cytokine propelled disease. J Bone Miner Res (2005) 0.93
FSH and TSH in the regulation of bone mass: the pituitary/immune/bone axis. Clin Dev Immunol (2013) 0.92
Osteogenic differentiation of dental follicle stem cells. Int J Med Sci (2012) 0.91
Dental pulp stem cells: osteogenic differentiation and gene expression. Ann N Y Acad Sci (2011) 0.90
Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin imbalance. J Clin Endocrinol Metab (2009) 0.90
Aortic valvular interstitial cells apoptosis and calcification are mediated by TNF-related apoptosis-inducing ligand. Int J Cardiol (2013) 0.89
High dickkopf-1 levels in sera and leukocytes from children with 21-hydroxylase deficiency on chronic glucocorticoid treatment. Am J Physiol Endocrinol Metab (2013) 0.88
Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol (2012) 0.87
TRAIL is involved in human osteoclast apoptosis. Ann N Y Acad Sci (2007) 0.86
Bone effects of biologic drugs in rheumatoid arthritis. Clin Dev Immunol (2013) 0.86
Mast cells in rheumatoid arthritis. Clin Rheumatol (2006) 0.85
Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis. Endocrinology (2007) 0.85
RANKL/OPG ratio and DKK-1 expression in primary osteoblastic cultures from osteoarthritic and osteoporotic subjects. J Rheumatol (2013) 0.85
Systemic effects of Wnt signaling. J Cell Physiol (2013) 0.84
IL-7 modulates osteoclastogenesis in patients affected by solid tumors. Ann N Y Acad Sci (2007) 0.84
Macrophages and angiogenesis in rheumatic diseases. Vasc Cell (2013) 0.84
Expression of vascular endothelial growth factor in normal, osteoarthritic and osteoporotic osteoblasts. Clin Exp Med (2011) 0.83
Genotype-phenotype correlation in juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene. Endocrine (2012) 0.83
The role of TNF-α and TNF superfamily members in the pathogenesis of calcific aortic valvular disease. ScientificWorldJournal (2013) 0.82
Gelatinase levels in male and female breast cancer. Biochem Biophys Res Commun (2002) 0.82
In vitro and in vivo angiogenic activity of osteoarthritic and osteoporotic osteoblasts is modulated by VEGF and vitamin D3 treatment. Regul Pept (2013) 0.81
The role of OPG/TRAIL complex in multiple myeloma: the OPG/TRAIL complex in an in vitro osteoclastogenesis model derived from human multiple myeloma-bone disease. Ann N Y Acad Sci (2006) 0.81
Nailfold capillaroscopic findings in systemic sclerosis related lung fibrosis and in idiopathic lung fibrosis. Joint Bone Spine (2010) 0.81
Immunomodulatory effects of vitamin D in peripheral blood monocyte-derived macrophages from patients with rheumatoid arthritis. Clin Exp Med (2013) 0.81
Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency. Biomed Res Int (2013) 0.81
Osteocalcin synthesis by human osteoblasts from normal and osteoarthritic bone after vitamin D3 stimulation. Clin Rheumatol (2004) 0.80
TRAIL effect on osteoclast formation in physiological and pathological conditions. Front Biosci (Elite Ed) (2011) 0.80
Osteoblasts display different responsiveness to TRAIL-induced apoptosis during their differentiation process. Cell Biochem Biophys (2013) 0.80
CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. J Bone Miner Res (2014) 0.80
TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what's new? Clin Exp Med (2012) 0.80
A new titanium biofunctionalized interface based on poly(pyrrole-3-acetic acid) coating: proliferation of osteoblast-like cells and future perspectives. J Mater Sci Mater Med (2007) 0.80
Two cases of distal extremity swelling with pitting oedema in psoriatic arthritis: the different pathological mechanisms. Rheumatol Int (2009) 0.79
Pathology of idiopathic encephaloceles into the middle ear. ORL J Otorhinolaryngol Relat Spec (2002) 0.79
Juvenile idiopathic arthritis: an update on clinical and therapeutic approaches. Ann Ital Med Int (2006) 0.77
Synovial fluid fibroblasts and lymphocytes support the osteoclastogenesis in human psoriatic arthritis. Ann N Y Acad Sci (2007) 0.77
Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clin Rheumatol (2005) 0.77
The formation of osteoclasts in multiple myeloma bone disease patients involves the secretion of soluble decoy receptor 3. Ann N Y Acad Sci (2010) 0.77
Metabolic syndrome in childhood leukemia survivors: a meta-analysis. Endocrine (2014) 0.76
Putative effects of potentially anti-angiogenic drugs in rheumatic diseases. Eur J Clin Pharmacol (2013) 0.76
Impact of biological therapy on spondyloarthritis. Eur J Clin Pharmacol (2014) 0.76
Correction: Relationship between Body Mass Composition, Bone Mineral Density, Skin Fibrosis and 25(OH) Vitamin D Serum Levels in Systemic Sclerosis. PLoS One (2015) 0.75
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease. Medicine (Baltimore) (2016) 0.75
Experimental model for studying the involvement of regulatory cytotoxic T cells in bone resorption. Methods Mol Biol (2014) 0.75
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Medicine (Baltimore) (2017) 0.75
Why TNF-α inhibition is not sufficient to avoid juxta-articular erosions in chronic arthritis? Intern Emerg Med (2011) 0.75
Combined effects of infliximab and methotrexate on rheumatoid arthritis osteoblastic cell metabolism. Clin Exp Med (2014) 0.75